JP2021535111A5 - - Google Patents

Info

Publication number
JP2021535111A5
JP2021535111A5 JP2021509794A JP2021509794A JP2021535111A5 JP 2021535111 A5 JP2021535111 A5 JP 2021535111A5 JP 2021509794 A JP2021509794 A JP 2021509794A JP 2021509794 A JP2021509794 A JP 2021509794A JP 2021535111 A5 JP2021535111 A5 JP 2021535111A5
Authority
JP
Japan
Prior art keywords
boraspiro
dodecane
aza
oxa
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021509794A
Other languages
English (en)
Japanese (ja)
Other versions
JP7441210B2 (ja
JP2021535111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/072341 external-priority patent/WO2020038983A1/en
Publication of JP2021535111A publication Critical patent/JP2021535111A/ja
Publication of JP2021535111A5 publication Critical patent/JP2021535111A5/ja
Application granted granted Critical
Publication of JP7441210B2 publication Critical patent/JP7441210B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021509794A 2018-08-22 2019-08-21 アルギナーゼインヒビタ及びその使用方法 Active JP7441210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862721113P 2018-08-22 2018-08-22
US62/721,113 2018-08-22
PCT/EP2019/072341 WO2020038983A1 (en) 2018-08-22 2019-08-21 Arginase inhibitors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021535111A JP2021535111A (ja) 2021-12-16
JP2021535111A5 true JP2021535111A5 (enExample) 2023-08-15
JP7441210B2 JP7441210B2 (ja) 2024-02-29

Family

ID=67742403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509794A Active JP7441210B2 (ja) 2018-08-22 2019-08-21 アルギナーゼインヒビタ及びその使用方法

Country Status (25)

Country Link
US (1) US11952392B2 (enExample)
EP (2) EP4371614A3 (enExample)
JP (1) JP7441210B2 (enExample)
KR (1) KR102668252B1 (enExample)
CN (1) CN112584900B (enExample)
AU (1) AU2019323663B2 (enExample)
CA (1) CA3109100A1 (enExample)
CL (1) CL2021000430A1 (enExample)
DK (1) DK3840837T3 (enExample)
EA (1) EA202190532A1 (enExample)
ES (1) ES2980252T3 (enExample)
FI (1) FI3840837T3 (enExample)
HR (1) HRP20240694T1 (enExample)
HU (1) HUE066903T2 (enExample)
IL (1) IL280924B2 (enExample)
LT (1) LT3840837T (enExample)
MA (1) MA53427B1 (enExample)
MX (1) MX2021002042A (enExample)
PL (1) PL3840837T3 (enExample)
PT (1) PT3840837T (enExample)
RS (1) RS65608B1 (enExample)
SG (1) SG11202101618PA (enExample)
SI (1) SI3840837T1 (enExample)
SM (1) SMT202400221T1 (enExample)
WO (1) WO2020038983A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019227607C1 (en) 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
MY206577A (en) * 2019-02-08 2024-12-24 Astrazeneca Ab Arginase inhibitors and methods of use thereof
EP4239652A4 (en) 2020-12-25 2024-06-05 Sumitomo Riko Company Limited Electrically conductive composition, sheet-form flexible electrode using same, and method for producing said electrode

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2560978B1 (en) 2010-04-22 2019-01-30 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
AU2016281620B2 (en) * 2015-06-23 2021-07-22 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US11291674B2 (en) * 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
WO2018119440A1 (en) 2016-12-22 2018-06-28 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
SG11202007739XA (en) 2018-02-17 2020-09-29 Astrazeneca Ab Arginase inhibitors and methods of use thereof
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2019205979A1 (zh) 2018-04-27 2019-10-31 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2021530565A5 (enExample)
JP2023036708A5 (enExample)
JP2022049005A5 (enExample)
JP2018531963A5 (enExample)
JP2022186995A5 (enExample)
JP2023002516A5 (enExample)
JP2024534014A5 (enExample)
JP2023500395A5 (enExample)
JP2014524442A5 (enExample)
JP2023519891A5 (enExample)
JP2023027066A5 (enExample)
JP2022511800A5 (enExample)
AU2023200724B2 (en) New crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide
JP2023522040A5 (enExample)
JP2014530818A5 (enExample)
JP2019504103A5 (enExample)
JP2023553930A5 (enExample)
CA2649796A1 (en) A novel crystalline form of lamivudine
JP2013538849A5 (enExample)
WO2016016766A2 (en) A process for the preparation of isavuconazonium or its salt thereof
JP2024095561A5 (enExample)
JP2015522037A5 (enExample)
JP2013520488A5 (enExample)
JP7433288B2 (ja) イサブコナゾニウム硫酸塩を精製するための方法
HRP20240694T1 (hr) Inhibitori arginaze i postupci njihove upotrebe